Threshold Pharmaceuticals, Inc. (THLD) Names Dr. Tillman Pearce as Chief Medical Officer
Threshold Pharmaceuticals, a biotechnology company, announced today that it has appointed Tillman Pearce, M.D., as its chief medical officer. Dr. Pearce will oversee development of the company’s TH-302, a clinical stage hypoxia-targeted cancer therapeutic currently being evaluated in a variety of cancers. TH-302 is presently undergoing a phase 3 trial in soft tissue sarcoma patients and a phase 2b trial in pancreatic cancer patients. Dr. Pearce has expertise in oncology drug development – both from the perspectives of large pharmaceutical companies and smaller entrepreneurial biotech companies. His almost two decades of international drug development experience will be valuable to Threshold…